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The embryonic formation ofmidbrain dopaminergic (mDA) neurons in vivo provides critical guidelines for the in vitrodifferentiation of
mDA neurons from stem cells, which are currently being developed for Parkinson’s disease cell replacement therapy. Bone morphoge-
netic protein (BMP)/SMAD inhibition is routinely used during early steps of stem cell differentiation protocols, including for the gener-
ation of mDA neurons. However, the function of the BMP/SMAD pathway for in vivo specification of mammalian mDA neurons is
virtually unknown.Here, we report that BMP5/7-deficientmice (Bmp5/;Bmp7/) lackmDAneurons due to reducedneurogenesis in
the mDA progenitor domain. As molecular mechanisms accounting for these alterations in Bmp5/; Bmp7/ mutants, we have
identified expression changes of the BMP/SMAD target genes MSX1/2 (msh homeobox 1/2) and SHH (sonic hedgehog). Conditionally
inactivating SMAD1 inneural stemcells ofmice in vivo (Smad1Nes) hampered thedifferentiationof progenitor cells intomDAneuronsby
preventing cell cycle exit, especially of THSOX6 (tyrosine hydroxylase, SRY-box 6) and THGIRK2 (potassium voltage-gated
channel subfamily-J member-6) substantia nigra neurons. BMP5/7 robustly increased the in vitro differentiation of human induced
pluripotent stem cells and induced neural stem cells to mDA neurons by up to threefold. In conclusion, we have identified BMP/SMAD
signaling as a novel critical pathway orchestrating essential steps of mammalian mDA neurogenesis in vivo that balances progenitor
proliferation and differentiation. Moreover, we demonstrate the potential of BMPs to improve the generation of stem-cell-derivedmDA
neurons in vitro, highlighting the importance of sequential BMP/SMAD inhibition and activation in this process.
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Significance Statement
We identify bone morphogenetic protein (BMP)/SMAD signaling as a novel essential pathway regulating the development of
mammalianmidbrain dopaminergic (mDA) neurons in vivo and provide insights into themolecularmechanisms of this process.
BMP5/7 regulateMSX1/2 (msh homeobox 1/2) and SHH (sonic hedgehog) expression to directmDAneurogenesis. Moreover, the
BMP signaling component SMAD1 controls the differentiation of mDA progenitors, particularly to substantia nigra neurons, by
directing their cell cycle exit. Importantly, BMP5/7 increase robustly the differentiation of human induced pluripotent and
induced neural stem cells to mDA neurons. BMP/SMAD are routinely inhibited in initial stages of stem cell differentiation
protocols currently being developed for Parkinson’s disease cell replacement therapies. Therefore, our findings on opposing roles
of the BMP/SMAD pathway during in vitromDA neurogenesis might improve these procedures significantly.
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Introduction
The major dopaminergic nuclei, the substantia nigra (SN) and
ventral tegmental area (VTA), are located in the midbrain and
play essential roles in brain functions and disorders. The SNmid-
brain dopaminergic (mDA) neurons are particularly vulnerable
to degeneration and their loss is characteristic of Parkinson’s
disease (PD) (Arenas et al., 2015). Stem-cell-derived mDA neu-
rons are critical for modeling of PD, drug screening, and cell
replacement therapy. The differentiation of stem cells to mDA
neurons requires the knowledge of the exact molecular mecha-
nisms directing the embryonic development of mDA neurons
in vivo.
After the induction of the ventral midbrain during embryo-
genesis, a distinct dopaminergic progenitor domain is specified.
The anterior extension of themDA progenitor domain is defined
by the EN1/DBX1microdomains (Nouri andAwatramani, 2017)
and the posterior boundary is defined by the caudal border of the
OTX2 expression domain at the mid-hindbrain junction. The
dorsal–ventral borders are defined by LMX1A expression that
overlaps with SHH (sonic hedgehog) expression of the midbrain
floor plate. In this domain, progenitors divide symmetrically to
expand their pool and switch to neurogenic division at the onset
of neurogenesis (Veenvliet and Smidt, 2014; Arenas et al., 2015;
Blaess and Ang, 2015). The balance between self-renewal and cell
cycle exit of dopaminergic neural progenitors, and the generation
of the appropriate numbers of postmitotic progeny is critical for
the proper formation ofmDAneurons. So far threemajor signal-
ing pathways activated by SHH, WNTs, and FGFs have been
identified in mammals to control proliferation and specification
of mDA progenitors in vivo (Ye et al., 1998; Prakash et al., 2006;
Saarima¨ki-Vire et al., 2007; Joksimovic et al., 2009; Andersson et
al., 2013; Blaess and Ang, 2015). These signaling pathways work
in concert with a series of transcription factors including OTX2,
LMX1B, LMX1A, EN1/2, FOXA1/2,NGN2, PITX3,MSX1/2, and
NURR1, which are important for progenitor cell responsiveness
to morphogens, differentiation, and survival (Zetterstro¨m et al.,
1997; Smidt et al., 2000; Simon et al., 2001; Brodski et al., 2003;
Puelles et al., 2003; Andersson et al., 2006a,b; Kele et al., 2006;
Ferri et al., 2007; Blaess and Ang, 2015; Sherf et al., 2015). Al-
though it has been postulated that additional signaling pathways
might be involved in the generation of mDA neurons, their iden-
tity has remained elusive.
Significant progress has been made in the generation of stem-
cell-derived mDA neurons. However, essential parameters are still
not fully controllable, including the consistency between experi-
ments, phenotypic identity of progenitors, and purity of mDA neu-
rons. Progress in the ability to determine these parameters are
essential because theyare linkeddirectly tograftoutcome,dyskinesia
side effects, and potential tumor formation after transplantation
(Politis et al., 2010; Arenas et al., 2015; Kirkeby et al., 2017). Current
in vitro differentiation protocols are based on the activation of the
three signaling pathways, SHH, WNT and FGF, which regulate the
formation of mammalian mDA neurons in vivo (Chambers et al.,
2009; Kriks et al., 2011; Salti et al., 2013; Arenas et al., 2015). There-
fore, the discovery of additional signaling pathways that determine
mDA development in vivo could critically advance the abilities to
manipulate in vitro conditions to achieve desired outcomes.
Bone morphogenetic proteins (BMPs) belong to the trans-
forming growth factor  superfamily. Phosphorylated SMAD1,
SMAD5, and SMAD8 are the major intracellular BMP signaling
pathway components. TheBMP/SMADpathway regulates awide
array of neurodevelopmental processes, including progenitor
proliferation, apoptosis, and differentiation (Chen and Panchi-
sion, 2007; Bond et al., 2012; Hegarty et al., 2013). Depending on
the cell type, extracellular environment, and developmental
stage, theymight enhance or inhibit these processes. A significant
progress in the directed neural differentiation of human pluripo-
tent stem cells was the discovery that blocking the BMP/SMAD
pathway in initial steps of the protocol led to highly efficient
neural conversion (Chambers et al., 2009; Kriks et al., 2011; Salti
et al., 2013). However, the role of BMPs during later stages of
mDA specification and maturation in vitro is unclear. Similarly,
the in vivo role of BMP/SMAD signaling in the formation of
mammalian mDA neurons is unknown. In the current study, we
investigated the function of BMP5/6/7 and SMAD1 in the forma-
tion of mDA neurons in vivo. Moreover, we explored the poten-
tial of BMP5/7 in the directed differentiation of human stem cells
to mDA neurons.
Materials andMethods
Mouse strains. The seGnJ mutation is a null allele at the Bmp5 locus
(Kingsley et al., 1992). Mice were provided by the Jackson Laboratory
and were genotyped as described previously (Solloway and Robertson,
1999). Bmp6- and Bmp7-deficient mice, kindly provided by Elizabeth J.
Robertson, were generated, genotyped, and maintained on an outbred
background as described previously (Solloway and Robertson, 1999;
Dudley et al., 1995). Bmp5/mice heterozygous for Bmp7 (Bmp7/)
weremated to obtain double homozygousBmp5/;Bmp7/ embryos.
As a control, we used Bmp5/;Bmp7/mutants that have one intact
Bmp7 allele and are viable and fertile. Smad1 fl/fl mice were mated to
Nestin-Cre;Smad1/ mice to generate Smad1 fl/;Nestin-Cre condi-
tional mutant mice and control littermates (Tronche et al., 1999; Huang
et al., 2002; Finelli et al., 2013). All mice were housed in a temperature-
controlled (21–23°C) environment under a 12 h light/dark cycle and had
ad libitum access to food and water in a pathogen-free animal facility. All
procedures and experimental protocols conducted on the animals were
approved by the Institutional Animal Care and Ethics committee at
Ben-Gurion University of the Negev (permit #IL-53-09-2016).
Embedding and sectioning of the tissue. For cryo-embedding, embryos
were processed by fixation in 4%paraformaldehyde for5 h [embryonic
day 9.5 (E9.5)/E10.5] or overnight [E12.5/postnatal day 0 (P0)/adult],
washed in PBS, pH 7.4, for 3  5 min, and immersed in 15% and 30%
sucrose PBS solution until the tissue sank. Tissue was then placed in
molds with optimal cutting temperature medium for 10–15 min before
freezing on a very thin layer of liquid nitrogen.
For paraffin embedding, after fixation, embryos were dehydrated by
immersion in serial ethanol solutions (50%, 70%, 80%, 90%, and 2
100%), isopropanol, and toluene before being embedded in paraffin.
Serial coronal or sagittal sections were subsequently cut on a cryostat
(14 m) or microtome (5 m) and mounted on Superfrost microscope
slides.
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Fluorescent/nonfluorescent immunochemistry. Microscope slides with
cryosections were placed at room temperature for 15–20 min, immersed
in ice-cold 100% ethanol for 10min, andwashed 3 5minwith PBS, pH
7.4, before incubation in blocking solution. Sections of the paraffin-
embedded tissue were rehydrated through a xylene and ethanol series
and washed with PBS, pH 7.4. Antigen retrieval was performed in the
next step using 0.001 M citric acid solution for 10 min at 95°C before
incubation in blocking solution. The incubationwith primary antibodies
was done overnight at 4°C. Slides were then rinsed in PBS (3  5 min)
and incubated for 1 h at room temperature with secondary antibodies
(Jackson ImmunoResearch) and DAPI (Sigma-Aldrich). HRP-DAB
staining kit (CTS 019; R&D Systems) was used for nonfluorescent BMP5
immunohistochemistry.
For the in vitro cultures, cells plated on glass coverslips were washed in
0.1 M PBS and fixed in 4% paraformaldehyde dissolved in 0.1 M PBS.
After washing, the cells were permeabilized with 0.3% Triton X-100 in
0.1 M PBS for 15 min and then incubated for 1 h in the blocking solution
containing 0.025% Triton X-100 and 10% fetal bovine serum (Invitro-
gen) in 0.1 M PBS. Subsequently, cells were incubated overnight at 4°C
with the primary antibodies diluted in the blocking solution containing
0.025% Triton X-100 and 5% fetal bovine serum in 0.1 M PBS. On the
next day, cells were washed in 0.1 M PBS/0.025% Triton X-100 (PBST)
and incubated with the corresponding fluorescent secondary antibodies
(Thermo Fisher Scientific). After washing with PBST, the cell nuclei were
stained with DAPI for 5 min and then washed again with distilled water.
Finally, coverslips were mounted onto adhesive slides using Aquapoly-
mount (Polyscience). ForDAT andGIRK2 staining, no permeabilization
was needed and Triton X-100 was omitted in all solutions.
Primary antibodies. Primary antibodies used for the in vivo study were
as follows: mouse anti-SHH (1:10), mouse anti-NKX6.1 (1:10), mouse
anti-ISLET1/2 (1:10), mouse anti-MSX1/2 (1:10), mouse anti-FOXA2
(1:10), mouse anti-NESTIN (1:10), mouse anti-EN1 (1:50) - all from
DSHB, rabbit anti-LMX1A (1:400, catalog #AB10533; Millipore), rabbit
anti-LMX1B (1:1000, gift from Dr. C. Birchmeier, MDC, Berlin), rabbit
anti-NURR1 (1:100, catalog #SC991; Santa Cruz Biotechnology),
mouse anti-NURR1 (1:100, catalog #376984; Santa Cruz Biotechnology)
mouse anti-neurogenin-2 (1:800, catalog #MAB3314; R&D Systems),
rabbit anti-TH (1:200, catalog #AB152; Millipore), mouse anti-TH
(1:200, catalog #MAB318; Millipore), rabbit anti-phospho-SMAD1/5/8
(1:200, #9511S Cell Signaling), sheep anti-BMP5 (1:10, catalog #AF6176;
R&D Systems), rabbit anti-phospho-histone-H3 (1:1000, catalog #06-
570; Millipore), rabbit anti-phospho-P38 (1:1000, catalog #4511 Cell
Signaling), rabbit anti-GIRK2 (1:200, catalog #APC-006; Alomone Lab-
oratories), rabbit anti-SOX6 (1:500, catalog #ab30455; Abcam), mouse
anti-POU4F1 (1:300, catalog #sc8429; Santa Cruz Biotechnology),
mouse anti-N-cadherin (1:200, catalog #610920; BD Biosciences), rabbit
anti-ZO1 (1:100, catalog #40-2200; Invitrogen), rabbit anti-KI67 (1:100,
catalog # ab16667; Abcam), rabbit anti-cleaved-caspase 3 (1:100, catalog
#3661; Cell Signaling Technology), rabbit anti-MAP-2 (1:200, catalog
#sc20172; Santa Cruz Biotechnology), rabbit anti--catenin (1:400, cat-
alog #9587s; Cell Signaling Technology), rabbit anti-SHH (1:50, catalog
#sc9024; Santa Cruz Biotechnology), rabbit anti-BMPR1B (1:100, catalog
#10537; Orbigen), rabbit anti-PITX3 (catalog #38-2850; Thermo Fisher
Scientific), mouse anti-BrdU (catalog #B2531; Sigma-Aldrich), rabbit anti-
CCND1(1:150, catalog #sc-450; Santa Cruz Biotechnology), rabbit anti-
phospho--catenin (1:200, catalog #9561s; Cell Signaling Technology),
rabbit anti-calbindin (1:500, catalog #D-28k; Swant), and rabbit anti- III
tubulin/TUJ1 (1:500, catalog #302 302; Synaptic Systems).
For the in vitro study, the following primary antibodies were used:
mouse anti-TH (1:1000, catalog #MAB318; Millipore), rabbit anti-TH
(1:1000, catalog #ab112; Abcam), rat anti-DAT (1:50, catalog #sc-32259;
SCBT), rabbit anti-LMX1A (1:1000, catalog # ab10533; Millipore), goat
anti-GIRK2 (1:200, catalog #ab65096; Abcam), and rabbit anti-calbindin
(1:1000, catalog #CB38; Swant).
In situ hybridization. For radioactive in situ hybridization, all sections
were processed according to Sherf et al. (2015) using 35S-labeled ribo-
probes against Bmp5, Bmp6, Bmp7, Th, Dat, and Nurr1.
For DIG-labeled in situ hybridization, mRNA probes were used to
detect Bmp7 andWnt1mRNA (Sherf et al., 2015, Tilleman et al., 2010).
Sections were postfixed in ice-cold 4% PFA for 10 min, digested with
proteinase K (2g/ml, 50mMTris, pH 8, 4mMEDTA) before acetylation
(1.3% TEA, 0.3% 10 M HCl, 0.5% acetic anhydride in DEPC-treated
water, 10 min), and permeabilized with PBT for 30 min. Prehybridiza-
tion was done for 2 h at 65°C and hybridization was done overnight at
65°C. Approximately 10 ng of probewas added to 200l of hybridization
solution per slide. The next day, slides were incubated with anti-
digoxigenin antibody at 4°C overnight. NBT/BCIP (Roche) was used for
color development.
In vivo proliferation assay. Pregnant females received intraperitoneal
injection of BrdU dissolved in 0.9% NaCl (100 mg/kg; B5002; Sigma-
Aldrich) 1 h before collection of embryos.
Quitting fraction. Twenty-four hours before harvesting embryos, preg-
nant females (E11.5) received intraperitoneal injection of BrdU (100
mg/kg; Sigma-Aldrich). Sections from E12.5 embryos were then triple
stained for KI67, BrdU, and LMX1A. The quitting fraction was obtained
by dividing the number of BrdU-labeled cells that had left the cell cycle
(KI67BrdU LMX1A) by the number of BrdU labeled cells that were
still cycling (KI67 BrdU LMX1A).
Area ratio analysis. MAP-2, KI67, and total midbrain area were
marked throughout the midbrain and measured using ImageJ software
and the values obtained were used to calculate MAP-2/total midbrain
and KI67/total midbrain ratios.
Cell density ratio analysis. For the cell density ratio analysis, a box was
drawn perpendicular to the ventricular surface next to mDA domain of
themidbrain. The boxwas divided in half to separate the neural tubewall
to apical and basal side. Each half of the box area wasmeasured in ImageJ
software. DAPI nuclei were counted within each half of the box, rostral
to caudal throughout the midbrain, and divided by its area to obtain
density values for apical and basal side. Apical density was divided by
basal density to obtain density ratio between the two.
Total fluorescence intensity of SHH and -catenin. For total immuno-
fluorescence intensity of SHH, a box was placed on the ventral midline
throughout rostral to caudal sections of the midbrain. Area, integrated
density, and mean gray value were measured using ImageJ software. A
box of the same size was placed directly adjacent to the SHH expression
domain andmeasurement was repeated. The total fluorescence intensity
ratio was then calculated by the formula Integrated Density of box1/
Integrated density of box2 (Burgess, 2010). For the total immunofluo-
rescence intensity measurements of -catenin, the mDA domain
constrained by NKX6.1 expression was outlined throughout the ventral
midbrain and the same parameters were measured. Integrated density
was normalized to area and background was subtracted for each image.
Cell culture. The derivation of the human induced pluripotent stem
cell (iPSC) and the humandirectly induced neural stem cells (iNSC) lines
has been described previously (Thier et al. 2012; Kadari et al., 2014;
Meyer et al., 2015; Kwok et al., 2017). The human fibroblasts used in this
study were obtained from a male individual skin punch biopsy after
obtaining informed consent and ethical clearance by the ethics commit-
tee of the University of Wu¨rzburg (ethical report #96/11, dated 10 June
2011) or from commercial sources (male foreskin). NSCswere generated
from iPSCs as described in Reinhardt (2013). Both NSC-derived iPSCs
and iNSCs were kept on growth factor-reduced Matrigel (Corning)-
coated plates in neural expansion medium consisting of 50:50 DMEM-
F12/Neurobasal medium with 1:50 B27 without vitamin A, 1:100 N2, 2
mM L-glutamine (all from; Invitrogen), 200 M ascorbic acid (Sigma-
Aldrich), 18 g/ml bovine serum albumin BSA fraction V (Applichem)
and supplemented with 4 M CHIR99021 (Axon Medchem), 5 M Alk5
inhibitor (Enzo), and 0.5 M purmorphamine (Miltenyi Biotec).
To generate mDA neurons, neural expansion medium was changed
2 d after splitting to dopaminergic differentiation medium consisting of
50:50 DMEM-F12/Neurobasal with 1:50 B27 with vitamin A, 2 mM
L-glutamine, 200 M ascorbic acid, and supplemented with 100 ng/l
FGF8 (PeproTech) and 1 M purmorphamine. When confluent, cells
were split using Accutase (Thermo Fisher Scientific) and 30,000 cells
were seeded in each well of a 12 well plate.Maturation started after 8 d by
withdrawal of FGF8 and the addition of 10 ng/ml BDNF (Stem Cell
Technologies), 10 ng/ml GDNF (PeproTech), 1 ng/ml TGF-beta3 (Pep-
roTech), and 500MdbcAMP. Then, 0.5Mpurmorphaminewas added
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to this medium for 2more days. In the BMP-or Noggin-treated cultures,
10 ng/ml BMP5 and BMP7 or 200 ng/mlNoggin (all fromR&DSystems)
were added to the medium. Cultures were analyzed 30 d after the start of
the differentiation (22 d in maturation conditions).
Cell quantification. For the in vivo studies paraffin-embedded coronal
sections of E10.5 embryos (5 m thick; 4 series), E12.5 embryos (5 m
thick; 6 series), E14.5 embryos (5mthick, 6 series), andP0 brains (5m
thick; 8 series) were used for cell quantification experiments. Represen-
tativemidbrain coronal sections revealing the distributions indicated are
presented in the figures. All positive/double-positive cells on every fourth
section (E10.5), sixth section (E12.5 and E14.5), or eighth section (P0)
were counted. All values were normalized toWT average (100%). ImageJ
software was used for cell counting.
For the in vitro studies, the stained cells were observed using a motor-
ized Leica DMi8 fluorescent inverted microscope equipped with a
Hamamatsu Orca Flash 4.0 V2 camera. The numbers of THTUJ1,
LMX1ATH, THGIRK2, and THCALB cells were determined
using Leica LasX and ImageJ software. From each experiment (n 2–4),
2 coverslips were analyzed and at least 7 random areas per coverslip were
counted. The number of quantified neurons for each experiment and
each condition was between 1000 and 3000.
Statistical analysis and experimental design. For both in vivo and in vitro
studies, two-tailed unpaired Student’s t test was used for the comparison
of the mean values. In the figures, *p  0.05, **p  0.01, and ***p 
0.001. Error bars represent SEM in all bar graphs. t values (t) and degrees
of freedom (df) are specified for each p-value reported in the Results.
For the in vivo studies, the number of experimental replicates (n) was
at least 3 (n 3 mutants/n 3 WT controls). In vivo experiments with
different n values are specified in the Results.
For the in vitro studies, the number of replicates was at least 2. For
TH/TUJ1 counting, 4 experiments from iPSC#1, 2 from iPSC#2, and 2
from iNSCs were performed.
Results
BMP5/7 are necessary for the generation of postmitotic
mDA neurons
To study the role of BMPs in mDA development, we first deter-
mined the expression of BMP5, BMP6, and BMP7 in the ventral
midbrain. To do this, we used mRNA in situ hybridization and
immunohistochemistry of WT embryos at different embryonic
days. During mDA neurogenesis at E12.5, Bmp5, Bmp6, and
Bmp7mRNAs were strongly expressed at themesencephalic flex-
ure where mDA neurons are formed (Fig. 1A–C). The BMP re-
ceptor 1B (BMPR1B), which plays a critical role in neuronal
differentiation (Panchision et al., 2001), was confined to the
NKX6.1-negative mDA domain at E12.5 (Fig. 1D). Also before
the onset of mDA neurogenesis at E10.5, Bmp7 mRNA expres-
sion, BMP5 immunoreactivity and phosphorylated SMAD-1/5/8
(p-SMAD1/5/8) were detected in the ventral midbrain close to
and within the mDA progenitor domain (Fig. 1E–G), suggesting
a role of these morphogens and SMAD1/5/8 in the formation of
mDA neurons.
To assess the function of BMP signaling in the development of
mDA neurons, we analyzed the formation of these neurons in
different Bmp single and compound mouse mutants. Changes
were not apparent in the formation of mDA neurons in
Bmp5/, Bmp6/, and Bmp7/ single mutants (Fig. 1H–J),
nor in Bmp5/;Bmp6/ and Bmp6/;Bmp7/ compound
mutants (Fig. 1K–L). In Bmp5/;Bmp7/ compound mu-
tants, however, postmitotic mDA neurons, marked by a highly
sensitive radioactive mRNA in situ hybridization probe (Fig.
1M,M) and NURR1 immunoreactivity (Fig. 1N–O	), as well as
-III tubulin TUJ1 (N–O	), were entirely absent.
Bmp5/;Bmp7/mutants could not be studied after E10.5
because most embryos subsequently die from heart defects, as
reported previously (Solloway and Robertson, 1999). Although
Bmp5/;Bmp7/ embryos are smaller in size, they do not dis-
play an overall delay in development and contain the same num-
ber of somite pairs as controls (Solloway and Robertson, 1999).
The absence of general patterning or regionalization defects
in the ventral midbrain and midbrain–hindbrain regions was
further demonstrated by normal Shh,Wnt1, and Fgf8 expression
in the midbrain floor plate and mid-hindbrain region at E10.5
(Solloway and Robertson, 1999). In addition, Phox2amRNA ex-
pression in cranial nerves III and IV,which formdirectly adjacent
to the mDA neurons at E9.5 (Pattyn et al., 1997), did not show
delayed onset of expression in mutants compared with WT (Til-
leman et al., 2010). Using ISLET-1/2 immunoreactivity to visu-
alize the nuclei of cranial nerve III, we observed a normal
induction of this nuclei at E9.5 (Fig. 1P,P), providing further
evidence that the lack of NURR1 expression in Bmp5/;
Bmp7/mutants is not caused by a general delay in neurogen-
esis in the ventral midbrain. Together, our data support the
conclusion that BMP5/7 are required for the formation of mDA
neurons.
BMP5/7 promote proliferation of mDA progenitors
To investigate themechanisms underlying the lack of postmitotic
mDA neurons in Bmp5/;Bmp7/ embryos, we next studied
the identity and relative extent of the mDA progenitor domain.
Previous experiments indicated that, although Bmp5/;
Bmp7/ embryos develop neurulation defects (Solloway and
Robertson, 1999), patterning abnormalities are not observed in
the floor plate, as visualized by Shh mRNA expression, or the
mid-hindbrain organizer, as visualized byWnt1 and Fgf8mRNA
expression (Solloway and Robertson, 1999).
At E9.5 and E10.5, expression patterns of LMX1B and
LMX1A, which mark the mDA progenitor domain, showed as in
WT a clear boundary to the adjacent NKX6.1 red nucleus pro-
genitor population (Fig. 2A–C).
Although boundary relationships were intact in the ventral
midbrain of Bmp5/;Bmp7/ mutants, the mDA progenitor
population, marked by LMX1A cells, was reduced by 39% at
E10.5 (Fig. 2C–C	; t(4) 2.89, *p 0.044). We then determined
whether the reduction in the number of mDA progenitor cells is
due to a proliferation defect or cell death. A reduction of 45% of
mitotic cells positive for LMX1A and phospho-histoneH3 (PH3)
(Fig. 2D–D	, t(4)  2.78, *p  0.049) in the mDA progenitor
domain ofBmp5/;Bmp7/ embryos at E10.5 indicated a pro-
liferation defect in mutants. These findings were supported by a
35% reduction of cells in the S-phase of the cell cycle that were
positive for both LMX1A and BrdU incorporation in mutants
(Fig. 2E–E	, t(4) 2.83, *p 0.047), as well as a reduced number
KI67 cells, all of which were LMX1A positive (data not shown).
In contrast, there was no increase in the levels of apoptosis in
these mutants (Fig. 2G,G).
In the midbrain, but outside of the mDA progenitor domain
of Bmp5/;Bmp7/ mutants, the number of mitotic cells
(LMX1APH3) was not significantly different from WT, but
showed a trend toward a decrease (Fig. 2H–H	; t(4)  1.38, p 
0.24). In contrast to WT embryos, in which BrdU cells were
distributed evenly along the apicobasal extension of the neural
tube wall, in Bmp5/;Bmp7/ mutants, BrdU and Ki67
cells clearly accumulated at the ventricular side of the neural tube,
leaving a BrdU/Ki67-negative territory on the basal side (Fig.
2I–J). Dividing the area covered by Ki67 cells by the total mid-
brain area indicated that the Ki67 share in total midbrain area
was reduced by 13%, suggesting a depletion of the progenitor
pool in mutants (Fig. 2J	; t(4) 3.76, *p 0.02). To rule out the
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possibility that this was caused by dispro-
portional density of the cells between the
apical and basal side of the neural tube in
Bmp5/;Bmp7/ mutants, we mea-
sured the density of cell nuclei (DAPI)
nuclei on the apical side (area 1) and basal
side (area 2) adjacent to themDA progen-
itor domain. No difference in the density
ratio between the two was observed (Fig.
2K–K	, t(4) 0.55, p 0.61). The altered
distribution of progenitor cells suggests
premature neurogenesis in the basal
plate progenitor domain. However,
these changes were not observed in the
mDA progenitor domain (Fig. 2F,F). As
for the rest of the midbrain, we did not
observe changes in apoptosis in the basal
plate of the mutant embryo (Fig. 2L,L).
In summary, BMP5/7 control prolifera-
tion of progenitor cells in the mDA pro-
genitor domain.
BMP5/7 are required for the induction
of MSX1/2 andmDA neurogenesis
We subsequently assessed neurogenesis
in the mDA progenitor domain of
Bmp5/;Bmp7/ mutants by visual-
izing the proneuronal transcription
factors MSX1/2, which are a direct down-
stream targets of the BMP signaling cas-
cade (Timmer et al., 2002; Tribulo et al.,
2003), and NGN2 (official gene symbol
Neurog2, MGI). These factors play a criti-
cal role in the generation ofmDAneurons
(Andersson et al., 2006a,b; Kele et al.,
2006). Consistent with previous reports
(Andersson et al., 2006a,b; Kele et al.,
2006), we found in the ventral midbrain
MSX1/2 specifically expressed in the
mDA progenitor domain (Fig. 3A). We
observed an 86% reduction in the number
of MSX1/2 cells even after normaliza-
tion to the number of LMX1A cells (Fig.
3A–A	, t(4)  9.4, ***p  0.00071). Like-
wise,NGN2 cells in themDAprogenitor
domain of Bmp5/;Bmp7/ mutants
were also reduced by 74% after normal-
ization to the number of LMX1A
cells (Fig. 3B–B	, t(4)  14.44, ***p 
0.000134). Moreover, Bmp5/;Bmp7/
Figure1. BMP5/7arenecessary for thegenerationofpostmitoticmDAneurons.mRNA in situhybridization (A–C,E,H–M) and
immunohistochemistry (D, F, G, N–P) on parasagittal (A–C, H–M) and coronal (D-G, N–P) sections of the mesencephalic
flexure at different developmental ages are represented. Bmp5 (A), Bmp6 (B), and Bmp7 (C) mRNAs are expressed at the mesen-
cephalic flexure at E12.5. At the same developmental time point, BMPR1B is expressed specifically in themDA progenitor domain
(D). At E10.5, Bmp7 mRNA is expressed lateral to the midline in the mDA progenitor domain (E). Red arrows indicate BMP5
immunoreactivity in the pial surface andmantle layer ofmDA progenitor domain (F ).White arrowheadspoint to cluster of cellswith
phosphorylated SMAD-1/5/8 (p-S1/5/8) immunoreactivity within themDA progenitor domain (G). Single Bmp5, Bmp6, and Bmp7 gene
deletiondoesnotaffect theformationofmDAneurons,asshownbythecomparisonofDatmRNAexpressiononparasagittal sectionsofWT
and Bmp5/ (H, H), Bmp6/ (I, I), and Bmp7/ (J, J) mutants at P0. Dat mRNA expression is unchanged
4
in Bmp5/;Bmp6/ mutants at P0 (K, K). Bmp6/;
Bmp7/ mutants did not show any obvious alterations in
mDA development, as indicated by normal Th mRNA expres-
sion at E11.5 (L, L). In contrast, in Bmp5/;Bmp7/mu-
tants at E10.5, Nurr1 mRNA (M, M) and NURR1 (N–O)
immunoreactivity were absent. In addition, the postmitotic
neuronal marker TUJ1 was coexpressed in NURR1 cells at
this time point inWT (N–N). Adjacent ocularmotor neurons
visualized by ISLET1/2 immunoreactivity were normally in-
duced inmutants at E9.5 (P) compared toWTs (P). Scale bars:
A–D,G–L 100m.G,P,P; 25m. E, F,N–O 25m.
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mutants showed a 43% reduction in postmi-
toticMAP-2 neurons in themDA progeni-
tor domain again following normalization to
the number of LMX1A cells (Fig. 3C–C	;
t(4) 3.19, *p 0.033).
In contrast, outside of the mDA pro-
genitor domain, Bmp5/;Bmp7/mu-
tants exhibited an increase of 10% in the
area containing MAP-2 postmitotic
neurons (Fig. 3E–E	; t(4) 3.98, **p 
0.01). An apparent increase in the number
of NGN2 and NKX6.1 cells that did
not reach statistical significance was also
observed (Fig. 3D–D	, t(4)  1.85, p 
0.14; Fig. 3F–F	, t(4) 1.67, p 0.17).We
conclude that BMP5/7 promote mDA
neurogenesis by regulating MSX1/2 and
NGN2 expression. In contrast, BMP5/7
appear to prevent premature neurogen-
esis in the midbrain basal plate outside
of the MSX1/2-positive mDA progenitor
domain.
BMP5/7 repress SHH expression in the
floor plate
Next, we studied the interaction of
BMP5/7 with the WNT and SHH path-
ways, which both play a key role in mDA
formation, by visualizing the expression
of WNT and SHH signaling compo-
nents in Bmp5/;Bmp7/mutants. Al-
though WNT signaling promotes the for-
mation of mDA neurons throughout
embryogenesis (Prakash et al., 2006; An-
dersson et al., 2013), SHH is necessary for
early steps of mDA progenitor induction
(Ye et al., 1998), but was suggested to re-
press mDA neurogenesis at later stages
(Joksimovic et al., 2009). Neither Wnt1
mRNA expression (Fig. 4A,A) nor total
-catenin immunofluorescence signal
strength (Fig. 4B–B, t(2)  0.07, p 
0.95; see Fig. 4C,C for higher magnifica-
tion), which plays a critical role in medi-
ating canonical WNT signaling, was
altered in Bmp5/;Bmp7/ mutants.
Furthermore, cell adhesion, which is de-
pendent on intact -catenin in the mDA
progenitor domain (Tang et al., 2009;
Chilov et al., 2011), was unperturbed in
themutants, as assessed by the normal ex-
pression of N-cadherin and ZO-1 (Fig.
4D–E). The number of cell nuclei with
accumulation of the GSK3- phosphory-
lated (S33/S37/Th41) -catenin form,
marked for degradation, was reduced by
Figure 2. BMP5/7 promote proliferation of mDA progenitors. The ventral midbrain of E9.5 Bmp5/;Bmp7/ mutants
shownormal patterning of themDAprogenitor domain as visualized by LMX1A, LMX1B, and SHH expression (A–B). At E10.5, the
boundary relationship between the mDA progenitor domain (LMX1A cells) and the adjacent red nucleus progenitor domain
(NKX6.1 cells) does not differ between the phenotypes (C, C). Quantification of LMX1AmDA progenitors at E10.5 indicates a
significant reduction in Bmp5/;Bmp7/mutants (C). Phosphorylated-histone H3 (PH3)-positive mitotic cells in the mDA
domain bordered by NKX6.1 expression were significantly reduced in Bmp5/;Bmp7/ mutants (D–D). The number of
BrdU-immunoreactive cells after 1 h short pulse incorporation coexpressing LMX1A (E–E) and KI67 (F, F) were decreased in
the mDA progenitor domain of Bmp5/;Bmp7/ mutants. In contrast, cleaved caspase-3 (c-caspase3) immunoreactivity
visualizing apoptotic nuclei did not show any obvious differences between genotypes (G, G). In the midbrain of E10.5
Bmp5/;Bmp7/mutants outside of the mDA progenitor domain, the number of PH3 cells showed a trend in reduction,
which did not, however, reach statistical significance (H–H). BrdU cell nuclei after 1 h short pulse incorporation accumulated in
the ventricular zone of Bmp5/;Bmp7/ mutants (I, I). Similar to BrdU cells, dividing KI67 cells were also found
predominantly in the ventricular side of the neural tube and the ratio of themidbrain area covered by the cells and total midbrain
area was significantly reduced (J–J). Densities of DAPI cell nuclei did not differ between the ventricular zone andmantle zone
of the neural tube (K–K). Cleaved caspase-3 immunoreactivity in the midbrain outside of the mDA progenitor domain did not
4
show any differences between genotypes (L, L). Two tailed
unpaired Student, t test *p 0.05. Scale bars: A–C, 100m;
D–L, 50m.
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60.7% in the mDA progenitor domain of Bmp5/;Bmp7/
mutants after normalization to the number of LMX1A cells
(Fig. 4F–F	, t(2) 5.325, *p 0.033). To further study WNT/-
catenin signaling, we analyzed the expression of its direct down-
stream target cyclin D1 (CCND1). CCND1 at E10.5 showed
strong ubiquitous expression throughout the midbrain in both
genotypes (Fig. 4G,G), with the exception of the LMX1AmDA
domain (Fig. 4G	–G	). Together, our results suggest that WNT/
–catenin signaling was not reduced in Bmp5/;Bmp7/mu-
tants. In contrast, the signal intensity of SHH immunoreactivity,
measured as a ratio of SHH signal between the midline (box 1)
and a region outside of SHH expression domain (box 2), was
nearly doubled in Bmp5/;Bmp7/ mutants (Fig. 4H–I	; t(4) 
3.186, *p 0.03).
To study which intracellular molecules mediate the effects of
BMPs in the formation of mDA neurons, we visualized the ca-
nonical BMP signaling components p-SMAD-1/5/8. Compared
with WT, Bmp5/;Bmp7/ mutants exhibited a 45% reduc-
tion in the number of p-SMAD-1/5/8-immunoreactive cells after
normalization to the number of LMX1A cells (Fig. 4J–J	, t(4)
4.66, ***p 0.0096). This suggests that SMAD-1/5/8mediate the
loss of mDA postmitotic neurons in mutants. Because BMP re-
ceptors can also initiate the activation of non-Smad signaling
pathways,mostly byMAP kinases (Mueller andNickel, 2012), we
studied the expression of p-ERK, p-JNK, and p-P38 in the ventral
midbrain of mutants. In contrast to p-ERK and p-JNK, which
were not detected in the mDA progenitor domain at E10.5 (data
not shown), p-P38 was strongly expressed there but did not show
Figure 3. BMP5/7 are required for the induction of mDA neurogenesis. The number of MSX-1/2 NGN2 and postmitotic MAP-2 cells in the LMX1A region were significantly reduced in
Bmp5/;Bmp7/mutants even after normalization to the reduced number of LMX1A cells (A–C). The number of NGN2 cells in the midbrain of Bmp5/;Bmp7/mutants outside
of themDAprogenitor domainwas not reduced (D–D) and the area covered byMAP-2 neurons comparedwith the totalmidbrain area showed an increase (E–E). The number of NKX6.1 cells
didnot showadecrease, but rather a trend towardan increase in themidbrainofBmp5/;Bmp7/mutantsoutsideof themDAprogenitordomain. Two tailedunpairedStudent, t test *p0.05, **p
0.01, ***p 0.001. Scale bars,A,A, 100m;B–F, 50m.
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any differences in expression compared with WT (Fig. 4K,K).
Together, our data suggest that one of the functions of BMP5/7 in
the development of mDA neurons is to provide a permissive
environment for mDA neurogenesis by repression of SHH ex-
pression in the midbrain floor plate.
SMAD1 is necessary for the formation of mDA neurons
Based on the lack of postmitotic mDA neurons (Fig. 1N–O	) and
the downregulation of p-SMAD1/5/8 (Fig. 4J–J	) in Bmp5/;
Bmp7/ mutants, we hypothesized that components of the
SMAD signaling pathway are mediating aspects of the effect of
Figure 4. BMP5/7 repress SHH expression in the medial floor plate. Wnt1 mRNA intensity in Bmp5/; Bmp7/ mutants is comparable to WT (A, A). The expression level measured by
fluorescence intensity in themDA domain (B) and the distribution of BETA-CATENIN (B–C), an essential component of the canonicalWNT signaling pathway, were unaltered between genotypes.
The cell to cell adhesionmarker N-CADHERIN and immunoreactivity of the tight junction protein ZO1 also do not showany differences in expression levels or distribution between genotypes (D–E).
S33/S37/Th41 phosphorylated beta-CATENIN formwas significantly reduced in in Bmp5/; Bmp7/mutants (F–F), while CCND1 was expressed in the midbrain, but not in the mDA domain
in WTs (G, G–G) nor in mutants (G). SHH expression levels are increased in the LMX1A mDA progenitor domain in Bmp5/; Bmp7/ mutants (H, H). SHH total fluorescence signal
intensitywas quantified by dividing ventralmidline signal (1) by the signal intensity in the region directly outside of the SHH expression domain (2) (I–I). The number of PHOSPHO-SMAD-1/5/8
cells in the mDA progenitor domain (arrowheads) was reduced in Bmp5/; Bmp7/ mutants, even after normalization to the reduction number of LMX1A cells (J–J). Expression of the
activatedMAP kinase P-38 (PHOSPHO-P38) in themDA domain did not show any differences between genotypes (K–K). Two tailed unpaired Student, t test *p 0.05, **p 0.01. Scale bars: A,
, I, I, E–F, 100m; B, B, F–G, J–K, 50m; C–E, G–G, 25m.
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BMP5/7 on mDA neuron formation. To test this hypothesis, we
assessed the formation of mDA neurons in mutants in which
Smad1 was conditionally inactivated using a Nestin-Cre driver
(Smad1Nes) (Tronche et al., 1999). Because, in thesemutants, Cre
activity starts to get activated in the ventral midbrain between
E10.5 and E11.5 (Vernay et al., 2005), we were able to assess the
role of the BMP/SMAD pathway at developmental time points
later than in Bmp5/;Bmp7/mutants.
In Smad1Nes mutants at E12.5, p-SMAD1/5/8 immunoreac-
tivity was profoundly reduced (Fig. 5A,A). Concomitantly, the
number of TH cells was significantly decreased by 19% at E12.5
compared with WT littermates (Fig. 5B–B	; t(10)  2.473, *p 
0.0329, n  6 WT; n  6 Smad1Nes) and NURR1 cells also
appeared reduced (Fig. 5C,C). The total number of LMX1A
cells did not differ significantly between the genotypes at this time
point (Fig. 5D–D	, t(2)  0.23, p  0.83, n  4 WT; n  4
Smad1Nes). The red nucleus, as visualized by POU4F1, was nor-
mal in Smad1 mutants (Fig. 5E–E	; t(4)  1.35, p  0.25). To
quantify the total number of cells undergoing mitosis, we
counted PH3 cells in the mDA progenitor domain laterally
Figure 5. SMAD1 is necessary for the formation of mDA neurons. Representative midbrain coronal sections of WT and Smad1 Nes mutant littermates at E12.5 and E14.5. phospho-SMAD-1/5/8-
positive cells (arrowheads) are strongly reduced in Smad1 Nes mutants (A, A). Midbrain TH neurons are significantly reduced in Smad1 Nes mutants (B–B). NURR1 postmitotic neurons appear
reduced in Smad1 Nes mutants (C, C), while the numbers of LMX1amDA progenitors (D–D) and POU1F4 red nucleus progenitors (E–E) show no statistical changes between phenotypes. In
mDA progenitor domain of Smad1 Nes mutants, the number of PH3mitotic cells flanked by NKX6.1 expression (F–F) and LMX1AKI67 cells (G–G) are significantly increased. The quitting
fraction calculated as a ratio of cells that have exited cell cycle (LMX1ABrdUKI67) and cells that are actively cycling (LMX1ABrdUKI67) is significantly reduced in Smad1 Nes knock-outs
(H–H). There is no difference in the numbers of LMX1ANGN2 cells between genotypes (I–I). In Smad1 Nesmutants, BETA-catenin is normally expressed (J–J). SHH has retracted in bothWT
andmutants from themidline at this developmental stage, asmeasured by comparing the signal intensity of themidline to the adjacent basal plate (K–K). Also at E14.5, the number of TH cells
is decreased in Smad1 Nesmutants. The reduction in THPITX3 cells exceeds the reduction observed in TH cells (L–L). Two tailed unpaired Student, t test *p0.05, **p0.01. Scale bars:B–C,E,
E, 100m;A,A,D–D, F–I, 50m; J, J, 25m.
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flanked by NKX6.1 cells. The Smad1 in-
activation strongly increased the number
of dividing cells in this domain by 42%
(Fig. 5F–F	; t(6) 3.05, *p 0.022, n 4
WT; n  4 Smad1Nes). In addition, the
number of mDA progenitors in the active
cell cycle (LMX1AKi67) was increased
by 29% (Fig. 5G–G	; t(5) 2.622, *p 
0.046, n  3 WT; n  4 Smad1Nes). To
investigate whether the decrease of mDA
neurons could be caused by a reduced
number of mDA progenitors exiting the
cell cycle, we assessed the quitting frac-
tion, calculated as the percentage of cy-
cling progenitors exiting the cell cycle
within 24 h of BrdU administration at
E11.5. To do so, we measured the frac-
tion of LMX1ABrdU cells that were
immunonegative for Ki67. We found
that the quitting fraction decreased sig-
nificantly from an average of 66% inWT
to an average of 44% in Smad1Nes con-
ditional mutant embryos (Fig. 5H–H	’;
t(5)  2.6, *p  0.048, n  3 WT; n  4
Smad1Nes). In contrast, the number of
LMX1ANGN2 cells was not changed
between genotypes (Fig. 5I–I	; t(6) 
1.176, p  0.28, n  4 WT; n  4
Smad1Nes). The unaltered expression of
-catenin in Bmp5/;Bmp7/ mu-
tants indicated normal canonical WNT
signaling in these animals (Fig. 5 J, J).
Moreover, SHH expression, which has
retracted from the midline at this devel-
opmental stage, showed no changes be-
tween genotypes (Fig. 5K,K; WTa/b 
0.55 
 0.06, Smad1Nesa/b  0.53 

0.09, t(4)  0.719, p  0.51).
Also at E14.5, the number of TH cells
was reduced in Smad1Nesmutants by 25%
(Fig. 5L–L	, t(4) 3.65, *p 0.02). Inter-
estingly, Smad1Nes mutants showed an
even stronger reduction in the number of
THPITX3 neurons at E14.5 of 50%
(Fig. 5L–L, L	; t(4)  9.09, **p 
0.00812). In summary, our data indicate
that, after E10.5, SMAD1-mediated BMP
signaling regulates neurogenesis of mDA
neurons by promoting the cell cycle exit of
mDA progenitors.
Figure 6. In postnatal P0 Smad1Nes mutants THSOX6 and THGIRK2 SN neurons are more affected than THCALB
VTAneurons. Coronal sectionsofWTand Smad1Nesmidbrains atP0andP7are represented. Thenumberof TH cells is significantly
reduced in Smad1Nes mutants (A–A). The red nucleus visualized by POU4F1 expression does not show differences beetwen the
genotypes (B–B). The numbers of THLMX1A (C–C), THNURR1 (D–D), THEN1 (E–E) and THPITX3 (F–F)
4
neurons were significantly reduced in Smad1Nes mutants. The
percentages of THSOX6 (G–G) and THGIRK2 (H–
H) SN neurons of the total midbrain TH neurons were re-
duced in Smad1Nes mutants. Conversely, the THCALB
portion of the total TH neurons did not show difference
beetwen the genotypes (I–I). Additionaly, TH neurons (J–
J) as well as THLMX1A (J, J, J) and THNURR1
(K–K) neurons showed significant reduction in Smad1Nes
mutants at P7. Two tailed unpaired Student, t test *p 0.05,
**p 0.01. Scale bars: A, A, C–H, J–K, 100m; I, I, 75
m; B, B, 25m.
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Figure 7. Timed delivery of BMP5/7 during in vitroDAdifferentiation causes an increase in the yield ofmDAneurons. Schematic representation of the protocol used to differentiate iPSC and iNSC
to DAneurons (A). Double Immunocytochemistry against TH and TUJ1 in iPSCs and iNSCs either in control or after 30 d of in vitroDAdifferentiation treatedwith BMP5/7 during thematuration phase
(B–E). Double immunocytochemistry against TH and the DA progenitor marker LMX1A (F–G), the DA markers GIRK2 (H) and CALB (I), as well as (Figure legend continues.)
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Postnatal Smad1Nes mutants show a predominant loss of
THSOX6 and THGIRK2 SN neurons
At P0, Smad1Nes mutants still exhibited a significant 28% reduc-
tion in the number of TH mDA neurons compared with con-
trols (Fig. 6A–A	; t(4)  3.47, *p  0.026). The number of
adjacent POU4F1 red nucleus cells between genotypes was un-
changed (Fig. 6B–B	; t(4)  1.01, p  0.37). Furthermore,
LMX1ATH showed a trend reduction by 18% (Fig. 6C–C	,
t(4) 1.36, p 0.245), whereas NURR1
THwere significantly
reduced by 30% (Fig. 6D–D	, t(4)  3.4, *p  0.027).
THPITX3 and THEN1 neurons in the mutants were re-
duced by 29% and 24%, respectively (Fig. 6E–F	, t(4) 3.49,*p
0.02 for E	 and t(4)  3.29, *p  0.03 for F	). To investigate
whether both VTA and SN neurons are reduced in the mutants,
we analyzed the expression of SOX6 andGIRK2, which have been
described to be preferentially expressed in SN mDA neurons
(Panman et al., 2014), as well as calbindin, preferentially ex-
pressed in the VTA. In Smad1Nes mutants, the reduction in
THSOX6 and THGIRK2 neurons was more severe than
the decrease in total TH neuronal populations, as indicated by a
significant decrease in the THSOX6/TH (Fig. 6G–G	, t(4)
2.8, *p 0.04) and THGIRK2/TH (Fig. 6H–H	, t(6) 2.48,
*p  0.048, n  4 WT; n  4 Smad1Nes) ratios in the mutants
comparedwithWT,whereas the THCALB/TH ratio did not
differ between the genotypes (Fig. 6I–I	, t(4) 0.89, p 0.424).
This particular strong effect on the number of SN neurons in the
mutants is likely a consequence of the changes in neurogenesis in
these mutants because p-SMAD1/5/8 immunoreactivity, was not
enriched in SN neurons at P0 in the WT (data not shown). Fi-
nally, the numbers of THLMX1A and THNURR1 neu-
rons remained significantly reduced at P7 (Fig. 6J–K	, t(4) 6.17,
**p 0.0035 for J	 and t(4) 6.63, **p 0.0027 for K	).
Together, these data indicate that SMAD1 is required partic-
ularly for the formation of THSOX6 and THGIRK2 neu-
rons, which are found predominantly in the SN.
BMP5/7 increase the yield of mDA neurons during in vitro
differentiation of hiPSCs and iNSCs
Wenext aimed to exploit this novel insight into the BMP/SMAD1
signaling role in mDA formation to modulate directed differen-
tiation of mDA neurons from human iPSCs (lines iPSC#1 and
iPSC#2) and a previously established iNSC line (Thier et al., 2012;
Kadari et al., 2014; Meyer et al., 2015; Kwok et al., 2017). For this
purpose, we modified a widely used mDA differentiation proto-
col (Reinhardt et al., 2013) that involves FGF8 and the SHH
agonist purmorphamine to specify dopaminergic progenitors
and a combination of BDNF, GDNF, dbcAMP, and TGFb3 to
enhance their maturation. We additionally applied BMP5 and
BMP7 during the maturation step and compared the outcome of
potential mDA neuron generation after 22 d of maturation with
non-BMP5/7-treated cultures (Fig. 7A). BMP5/7 treatment re-
sulted in a strong increase in the numbers of TH neurons
in both human iPSC lines and in iNSC-derived cultures, as mea-
sured by costaining for TUJ1 and TH (Fig. 7B–E). Quantifica-
tion revealed a significant 2- to 3-fold increase of THneurons in
BMP5/7-treated cultures compared with untreated cultures (Fig.
7K, iPSC #1: t(6) 6.759, p 0.0005; iPSC #2: t(2) 39.84, p
0.0006, iNSC: t(2) 57.99, p 0.0003, unpaired t test). Because
TH expression is not restricted to mDA neurons, we extended
our analysis in iPSC-derived cultures to various alternative
mDA markers including LMX1A, DAT, GIRK2, and CALB.
LMX1Awas also analyzed in iNSC-derived cultures. We found
numerous cells double-immunoreactive for TH/LMX1A (Fig.
7F–G), GIRK2/TH (Fig. 7H ), CALB/TH (Fig. 7I ), and
DAT/TH (Fig. 7J ), confirming their mDA identity.
THGIRK2 double-positive cells were found more fre-
quently (8 
 0.6%) than THCALB (3 
 0.4%) cells. In
addition, we used TH/LMX1A costaining for comparative
quantification and found fourfold more THLMX1A cells
in BMP5/7-treated iPSC-derived cultures compared with con-
trols (Fig. 7O; t(2)  80.88, p  0.0002, unpaired t test). Fi-
nally, to test the necessity of BMP5/7 for the generation of
mDA neurons, we blocked the BMP pathway during the mat-
uration phase (D8 to D30) using Noggin in both iPSC lines.
The results revealed a significant reduction (iPSC #1: t(2) 
4.482, p 0.0463; iPSC #2: t(2) 7.207, p 0.0187, unpaired
t test) in the number of THTUJ1 in both Noggin-treated
cultures (Fig. 7L–N ), indicating a blockade in the generation
of mDA neurons. In summary, BMP5 together with BMP7 are
able to promote robustly and specifically differentiation of
human stem-cell-derived mDA neurons.
Discussion
We demonstrated that Bmp5/;Bmp7/ mutants show aber-
rant MSX1/2 and SHH expression associated with ablated mDA
progenitor proliferation and neurogenesis. Furthermore, the
conditional inactivation of Smad1 at midgestation impeded dif-
ferentiation of progenitor cells into mDA neurons by preventing
cell cycle exit, particularly of THSOX6 and THGIRK2 SN
neurons. Finally, we found that BMP5/7 increased the efficiency
of stem-cell-derived dopaminergic differentiation significantly.
Interactions of BMPs withMSX1/2, SHH, andWNTs in the
formation of mDA neurons
MSX1/2 mediate as direct BMP/SMAD targets the development
of different organ systems (Timmer et al., 2002; Tribulo et al.,
2003).MSX1, which is exclusively expressed in themDA progen-
itor domain in the ventral midbrain, promotes in cooperation
with LMX1A, NGN2 expression, and neural differentiation (An-
dersson et al., 2013). These data suggest that BMP5/7 regulate
mDA neurogenesis by controlling the expression of MSX1/2
directly.
There are many examples in which SHH and WNTs closely
interact with BMPs in the generation of non-mDAneuronal pop-
ulations. Therefore, an interaction of all three signaling pathways
could provide the permissive environment specific for mDA
neurogenesis.
Starting atE8.0, SHH signaling is important for the forma-
tion of the SHH/FOXA2-positive floor plate and mDA progeni-
tor domain (Ye et al., 1998; Blaess et al., 2006; Perez-Balaguer et
al., 2009). However, at the onset of mDA neurogenesis, SHH
inhibits floor plate mDA neurogenesis (Joksimovic et al., 2009).
WNT/-catenin signaling is necessary and sufficient for antago-
nizing SHH and thereby creating a permissive environment for
4
(Figure legend continued.) the mature DA marker DAT (J) are shown. The percentage of
THTUJ1 in two iPSC lines (iPSC #1 and #2) and one iNSC line is twofold to threefold in-
creased in cultures treated with BMP5/7 compared with untreated controls (K). Double immu-
nocytochemistry against TH and TUJ1 in 2 iPSC lines either in control or in cultures treated with
Nogginduring thematurationphase is shown (L,M). Thepercentageof THTUJ1 in two iPSC
lines (iPSC #1 and #2) is 50%decreased after blocking the BMPpathwaywithNoggin compared
with untreated controls (N). The percentage of THLMX1A in iPSCs is increased in the
treated BMP cultures compared with untreated controls (O). All staining and counting were
analyzed after 30 d of DA in vitro differentiation. Two tailed unpaired Student, t test *p 0.05,
***p 0.001. Scale bars indicate 100m if not specified otherwise. D, Days in vitro.
Jovanovic, Salti et al. • BMP/SMAD Pathway in Dopaminergic Differentiation J. Neurosci., February 14, 2018 • 38(7):1662–1676 • 1673
mDA neurogenesis (Joksimovic et al., 2009; Tang et al., 2009,
2010). The upregulation of SHH expression in Bmp5/;
Bmp7/mutants therefore indicates that the restriction of SHH
availability by BMPs could provide one mechanism by which
BMPs control mDA neurogenesis. Interestingly, the property of
BMP7 to reduce SHH expression is not limited to the midbrain.
Previous experiments have demonstrated that misexpression of
BMP7 in the hindbrain, where it is normally not expressed, at-
tenuates the expression of SHH in the floor plate (Arkell and
Beddington, 1997). Moreover, the addition of BMP7 to explant
cultures of the hypothalamus downregulated SHH expression
(Manning et al, 2006). One function of BMPs in the development
of mDA neurons is to create a permissive environment for mDA
neurogenesis by restricting SHH expression.
Examples of crosstalk betweenWNTs and BMPs in regulating
the development of non-mDA neurons raise the possibility that
the effects of BMPs on mDA neurogenesis are mediated through
WNTs. However, the unaltered expression ofWNT/-catenin in
Bmp5/;Bmp7/ mutants does not suggest that this pathway
is downstream of BMPs. Moreover, WNT/-catenin and BMP/
SMAD mutants show distinct phenotypes, further suggesting
that WNT/-catenin and BMP/SMAD control mDA neuron
development through separate pathways. In Wnt1/ and
Wnt1/;Wnt5/ mutants, TH, LMX1A, and NURR1
cells are absent in the floor plate and instead are ectopically lo-
cated laterally (Andersson et al., 2013). The early inactivation of
-catenin using a SHH-Cre driver leads to the detachment of
progenitor cells from the floor plate that become free floating in
the enlarged ventricle and a loss of cell adherens junctions (Tang
et al., 2009), which we did not observe in our mutants. Similarly,
deleting-catenin in a temporally controlledmanner up to E10.5
using a tamoxifen-inducible R26-CreERT2driver leads to delam-
inated cells and loss of ZO1 and N-cadherin immunoreactivity,
indicative of cell adhesion defects (Chilov et al., 2011). Impor-
tantly, using the nestin-Cre driver, as in our study, to inactivate
-catenin does not lead to changes in the development of mDA
neurons (Joksimovic et al., 2009). Although we have no indica-
tion that the loss of mDA neurons in BMP/SMAD mutants is
caused by reduced WNT signaling, our data do not allow us to
exclude that theWNT pathway has some role in the BMP/SMAD
effects on mDA neurogenesis. Further experiments will be
needed to address this issue, including the functional relevance of
changes in phosphorylated -catenin in BMP mutants.
Early and late effects of BMP/SMAD signaling on
mDA neurogenesis
In contrast to Bmp5/;Bmp7/ mutants, which do not de-
velop any postmitotic mDA neurons, Smad1Nes mutants show a
reduction in the number of these cells. SMAD1/5/8 are the BMP-
receptor-regulated SMADs that compose the key components of
the canonical BMP signaling cascade (Katagiri and Watabe,
2016). Based on the lack of SMAD8 expression during midgesta-
tion and the apparent normal CNS development in Smad8 mu-
tants (Arnold et al., 2006), there is no indication that SMAD8
mediates the effects of BMP5/7 on the formation of mDA neu-
rons. In contrast, Smad1 and Smad5 mutant mice phenocopy
aspects of Bmp5/;Bmp7/ mutants and also die at E10.5
(Chang et al., 1999; Arnold et al., 2006). Moreover, SMAD1 and
SMAD5 were shown to function cooperatively in response to
BMPs during embryogenesis (Arnold et al., 2006). Therefore,
these data suggest that SMAD5 could compensate for the loss of
SMAD1 in Smad1Nes mutants, leading to a milder mDA pheno-
type of Smad1Nes mutants compared with Bmp5/;Bmp7/
mutants.
Although Bmp5/;Bmp7/ mutants show a decrease in
mDA progenitor cell proliferation at E10.5, Smad1Nes mutants
show an increase at E12.5. The downregulation of p-SMAD1/5/8
and the unaltered expression of the investigated noncanonical
BMP pathway in Bmp5/;Bmp7/ mutants suggest that the
differences in cell proliferation are unlikely to be caused by dis-
ruptions of different signaling pathways. Instead, the different
phenotypesmight be explained by the different time points when
we studied the consequences of BMP/SMAD inactivation. This
suggests a different response of forming mDA neurons to the
BMP/SMAD pathway at different stages of their development.
There is ample evidence that BMP/SMADs exert different in-
fluences during embryogenesis on the development of a cell lin-
eage that are sometimes even opposing. Cell populations that are
affected differentially by BMPs during early and later stages of
their development include cortical neurons, astroglial lineages
(Mabie et al., 1999;Mehler et al., 2000), and neurons in the spinal
cord (Yamauchi et al., 2008). Interestingly, there is a dependency
of NGN2 expression on BMP7 in the cortex, which is confined to
E14.5 (Segklia et al., 2012).
The molecular mechanisms explaining why a cell lineage re-
sponds differentially to BMPs during its development are poorly
understood. However, there is evidence that the sequential ac-
tions of BMP receptors are critically involved in this process
(Panchision et al., 2001). Neural precursor cells ubiquitously ex-
press BMPR1A fromearly development on. In contrast, BMPR1B
starts to be expressed only later during embryogenesis, at the
onset of neuronal differentiation (Panchision et al., 2001).
BMPR1B expression is induced by BMPR1A and, interestingly, is
repressed by SHH. When BMPR1B is activated, it causes mitotic
arrest and thereby limits the number of precursor cells, leading to
terminal differentiation in midgestation embryos (Panchision et
al., 2001). These data could explain the differences in progenitor
proliferation observed in Bmp5/;Bmp7/ mutants at E10.5
and Smad1Nes mutants at E12.5. At the onset of mDA neuro-
genesis at E10.5, the reduced BMPR1A/SMAD activation in
Bmp5/;Bmp7/ mutants is responsible for the reduced
cell proliferation. During later stages at E12.5, when SMAD1
mediates the differentiating effects of BMPR1B, which we
found to be confined in the ventral midbrain to the mDA
progenitor domain, loss of this signaling component attenu-
ates cell cycle exit and differentiation of mDA neurons. Future
experiments aiming to understand how BMPR1A and
BMPR1B mediate their differential effects on mDA develop-
ment will provide essential insights into the role of the BMP/
SMAD signaling in the formation of these neurons.
BMP5/7 enhance directed differentiation into mDA neurons
in vitro
Primary cultures derived from rodent embryonicmesencephalon
indicate the potential of different BMPs to inducemDA differen-
tiation and promote the survival of these neurons in vitro (Jordan
et al., 1997; Hegarty et al., 2014). More recently, BMP7 has been
reported to increase the yield of pramipexole-inducedmDAneu-
rons from forebrain-derived human neural stem cells and BMP2
was demonstrated to increase the number of LMX1A and FOXA2
immunoreactive cells (Liu et al., 2013; Yang et al., 2016).Many in
vitro studies have reported a successful differentiation of mouse
and human PSCs toward mDA neurons and demonstrated the
efficacy of these cells to integrate and survive in animal models of
PD (Kriks et al., 2011; Salti et al., 2013; Grealish et al., 2014;
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Kirkeby et al., 2017). Most of these studies are based on a floor
plate protocol, in which neural stem cells are specified and differ-
entiated toward a midbrain fate by triggering SHH and FGF8
signaling pathways to mimic what is known from in vivo mid-
brain development. However, these research grade protocols face
several challenges, especially the considerable variability between
experiments and the low purity of PSC-derived mDA neurons,
which lies between15% and 30% (Kriks et al., 2011; Salti et al.,
2013; Kirkeby et al., 2017). This leads us to suggest that essential
signaling molecules are still missing in the currently used proto-
cols. In addition, most of these recent protocols inhibit BMP/
SMAD signaling early during the neural induction phase to
induce the neural conversion of PSCs (Chambers et al., 2009;
Kirkeby et al., 2017).
We found that BMP5/7, if applied in vitro later during the
maturation phase, enhanced the formation of mDA neurons ef-
ficiently. Therefore, our data suggest that, although BMP/SMAD
inhibition is important for neural conversion at the beginning of
the differentiation protocol, it is essential to switch later during
the maturation phase to BMP activation. Together, our results
on the sequential role of the BMP/SMAD pathway on progenitor
proliferation, cell cycle exit, and neurogenesis provide critical
information to more efficiently program stem cells to a desired
phenotype, increase graft outcome, and reduce side effects after
transplantation.
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